Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies

Experimental Hematology

Volumn 27, Issue 7, 1999, Pages 1210-1218

  Naparstek, Elizabeth ^a   Delukina, Maria ^a   Or, Reuven ^a   Nagler, Arnon ^a   Kapelushnik, Joseph ^a   Varadi, Gabor ^a   Strauss, Nurit ^a   Cividalli, Gabriel ^a   Aker, Mahmed ^a   Brautbar, Chaim ^a   Waldmann, Herman ^b   Hale, Geoff ^b   Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Campath 1; Engraftment; T cell depletion

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN;

ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ALLOGRAFT; APLASTIC ANEMIA; ARTICLE; BLOOD DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GRAFT FAILURE; GRAFT REJECTION; HEMOGLOBINOPATHY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; THALASSEMIA;

ABO BLOOD-GROUP SYSTEM; AGE FACTORS; ANEMIA, APLASTIC; ANIMALS; ANTIBODIES, MONOCLONAL; BETA-THALASSEMIA; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; LEUKEMIA; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; LYMPHOCYTE DEPLETION; MALE; MULTIVARIATE ANALYSIS; NUCLEAR FAMILY; RATS; SEX FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 20244383278     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(99)00052-1     Document Type: Article

References (55)

1. Storb R., Prentice R.L., Thomas E.D. Marrow transplantation for treatment of aplastic anemia. an analysis of factor associated with graft rejection N Engl J Med. 296:1977;61.
2. Storb R., Prentice R.L., Thomas E.D., Appelbaum F.R., Deeg H.J., Doney K., Feffer A., Goodell B.W., Mickelson E., Stewart P., Sullivan K.M., Witherspoon R.P. Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anemia. Br J Haematol. 55:1983;573.
3. Hale G., Cobbold S., Waldmann H. T cell depletion with CAMPATH 1 in allogeneic bone marrow transplantation. Transplantation. 45:1988;753.
4. Kernan N.A., Collins N.H., Juliano L., Cartagena R., Dupont B., O'Reilly R.J. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-vs-host disease. Blood. 68:1986;770.
5. Antin J.H., Bierer B.E., Smith B.R., Ferrara J., Guinan E.C., Sieff C., Golan D.E., Macklis R.M., Tarbell N.J., Lynch E., Richert T.A., Blythman H., Bouloux C., Rappeport J.M., Burakoff S.J., Weinstein H.J. Selective depletion of bone marrow T lymphocytes with anti CD5 monoclonal antibodies. effective prophylaxis for graft versus host disease in patients with hematological malignancies Blood. 78:1991;2139.
6. Frame J.N., Collins N.H., Cartagena T., Waldmann H., O'Reilly Dupont B., Kernan N.A. T cell depletion of human bone marrow. Transplantation. 47:1989;984.
7. Prentice H.G., Janossy G., Skeggs D., Blacklock H.A., Bradstock K.F., Goldstein G., Hoffbrand A.V. Use of anti T cell monoclonal antibody OKT3 to prevent acute graft versus host disease in allogeneic bone marrow transplantation for acute leukemia. Lancet. 1:1982;700.
8. Filipovich A.H., Ramsay N., Warentin P., McGleave P.B., Goldstein G., Kersey J. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft versus host disease in allogeneic histocompatible bone marrow transplantation. Lancet. 2:1982;1266.
9. Kernan N.A., Bordignon C., Heller G., Cunningham I., Castro-Malaspina H., Shank B., Flomenberg N., Burns J., Yang S.Y., Black P., Collins N.H., O'Reilly R.J. Graft failure after T cell depleted human leukocyte antigen identical marrow transplants for leukemia. I. Analysis of factors and results of secondary transplants Blood. 74:1989;2227.
10. Mitsuyasu R.T., Champlin R.E., Gale R.P., Ho W.G., Lenarsky C., Winston D. Treatment of donor bone marrow with monoclonal anti T cell antibody and complement for prevention of graft vs host dosease. Ann Int Med. 105:1985;20.
11. Patterson J., Prentice H.G., Brenner M.K., Gilmore M., Janossy G., Ivory K., Skeggs D., Morgan H., Lord J., Blacklock H.A., Hoffbrand A.V., Apperly J.F., Goldman J.M., Burnett A., Gribben J., Alcorn M., Pearson C., McVickers I., Hann I.M., Reid C., Wardl D., Gravett P.J., Bacigalupo A., Robertson A.G. Graft rejection following HLA matched T lymphocyte depleted bone marrow transplantation. Br J Haematol. 63:1986;221.
12. Martin P.J., Hansen J.A., Buckner C.D., Sanders J.E., Deeg H.J., Stewart P., Appelbaum F.R., Clift R., Fefer A., Witherspoon R.P., Kennedy M.S., Sullivan K.M., Flournoy N., Storb R., Thomas E.D. Effects of in vitro depletion of T cell in HLA-identical allogeneic marrow grafts. Blood. 66:1985;664.
13. Martin P.J., Hansen J.A., Torok-Storb B., Durnam D., Przepiorka D., O'Quigley J., Sanders J.E., Sullivan K.M., Witherspoon R.P., Deeg H.J., Appelbaum F.R., Stewart P., Weiden P., Doney K., Buckner C.D., Clift R., Storb R., Thomas E.D. Graft failure in patients receiving T cell depleted HLA identical allogeneic marrow transplants. Bone Marrow Transplant. 3:1988;445.
14. O'Reilly R.J., Collins N.H., Kernan N.A., Brochstein J., Dinsmore R., Kirpatrick D., Siena S., Keever C., Jordan B., Shank B., Wolf L., Dupont B., Reisner Y. Transplantation of marrow depleted of T cells by soybean lectin agglutination and E rosette depletion. major histocompatibility complex related graft resistance in leukemic transplant recipients Transplant Proc. 17:1985;455.
15. Blaise D., Gravis G., Maraninchi D. Long term follow up of T cell depletion for bone marrow transplantation. Lancet. 1:1993;51.
16. Apperley J.F., Lones L., Hale G., Waldmann H., Hows J., Rombos Y., Tsatalas C., Marcus R.E., Goolden A.W.G., Gordon-Smith E.C., Catovsky D., Galton D.A.G., Goldman J.M. Bone marrow transplantation for patients with chronic myeloid leukemia. T cell depletion with CAMPATH 1 reduces the incidence of GVHD but may increase the risk of leukemic relapse Bone Marrow Transplant. 1:1986;53.
17. Barrett A.J., Horowitz M.M., Gale R.P., Biggs J.C., Camotta B.M., Dicke K.A., Gluckman E., Good R.A., Herzig R.H., Lee M.B. Marrow transplantation for acute lymphoblastic leukemia. factors affecting relapse and survival Blood. 74:1989;862.
18. Marmont A.M., Horowitz M.M., Gale R.P., Sobocinski K., Ash R.C., van Bekkum D.W., Champlin R.E., Dicke K.A., Goldman J.M., Good R.A., Herzig R.H., Hong R., Masaoka T., Rimm A.A., Ringden O., Speck B., Weiner R.S., Bortin M.M. T cell depletion of HLA-Identical transplants in leukemia. Blood. 78:1991;2120.
19. Ash R.C., Horowitz M.M., Gale R.P., van Bekkum D.W., Casper J.T., Gordon-Smith E.C., Henslee P.J., Kolb H.J., Lowenberg B., Masaoka T., McGlave P.B., Rimm A.A., Ringden O., van Rood J.J., Sondel P.M., Vowels M.R., Bortin M.M. Bone marrow transplantation from related donors other than HLA-identical siblings. effect of T cell depletion Bone Marrow Transplant. 7:1991;443.
20. Hale G., Waldmann H. Control of graft vs. host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant. 13:1994;597.
21. Hale G., Waldmann H. CAMPATH-1 monoclonal antibodies in bone marrow transplantation. J Hematother. 3:1994;15.
22. Hale G., Waldmann H. Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. Bone Marrow Transplant. 17:1996;305.
23. Martin P. Determinants of engraftment after allogeneic marrow transplantation. Blood. 79:1992;1647.
24. Champlin R.E., Feig S.A., Ho W.G., Gale R.P. Graft failure following bone marrow transplantation. it's biology and treatment Exp Hematol. 12:1984;728.
25. Bordignon C., Keever C.A., Small T.N., Flomenberg N., Dupont B., O'Reilly R.J., Kernan N.A. Graft failure after T cell depleted human leukocyte antigen identical marrow transplants for leukemia. II. In vitro analyses of host effector mechanisms Blood. 74:1989;2237.
26. Bunjes D., Heit W., Arnold R., Schmeiser T., Weisneth M., Carbonell F., Porzsolt F., Raghavachar A., Heimpel H. Evidence of the involvement of host derived OKT8 positive T cells in the rejection of T-depleted HLA-identical bone marrow grafts. Transplantation. 43:1987;501.
27. Murphy W.J., Kumar V., Cope J.C., Bennet M. An absence of T cells in murine bone marrow allografts leads to increased susceptibility to rejection by natural killer cells and T cells. J Immunol; 144:1990;3305.
28. Atkinson K., Norrie S., Chan P., Downs K., Biggs J. Lack of correlation between nucleated bone marrow cell dose, marrow CFU-GM dose or marrow CFU-E dose and the rate of HLA-identical sibling engraftment. Br J Haematol. 60:1985;245.
29. Waldmann H., Hale G., Cividalli G., Weshler Z., Manor D., Rachmilewitz E.A., Polliak A., Or R., Weiss L., Samuel S., Brautbar C., Slavin S. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet. 1:1984;483.
30. Naparstek E., Hardan I., Ben-Shahar H., Cohen P., Mumcuglu M., Samuel S., Weiss L., Hale G., Waldmann H., Slavin S. A new method for prevention of graft versus host disease (GVHD). Exp Hematol. 17:1989;723a. (abstr).
31. Naparstek E., Or R., Nagler A., Cividalli G., Engelhard D., Aker M., Gimon Z., Manny N., Sacks T., Tochner Z., Weiss L., Samuel S., Brautbar H., Hale G., Waldmann H., Steinberg S.M., Slavin S. T cell depleted allogeneic bone marrow transplantation for acute leukemia using CAMPATH-1 antibodies and post transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol. 89:1995;506.
32. Slavin S., Naparstek E., Weshler Z., Brautbar H., Rachmilewitz E.A., Fuks Z. Bone marrow transplantation for severe aplastic anemia in HLA identical siblings using total lymphoid irradiation (TLI) and cyclophosphamide. Transplant Proc. 15:1982;668.
33. Cividalli G., Brautbar C., Weiss L., Samuel S., Gale G., Waldmann H., Rachmilewitz E.A., Slavin S. Bone marrow transplantation in beta thalassemia major using T cell depleted HLA identical bone marrow allografts. Bone Marrow Transplant. 1(Suppl.):1986;337.
34. Naparstek E., Hardan Y., Ben-Shahar M., Nagler A., Or R., Mumcuoglu M., Weiss L., Samuel S., Slavin S. Enhanced marrow recovery by short preincubation of marrow allografts with human recombinant interleukin 3 and granulocyte-macrophage colony-stimulating factor. Blood. 80:1992;1673.
35. Naparstek E., Or R., Nagler A., Cividalli G., Engelhard D., Gimon Z., Manny N., Weiss L., Samuel S., Brautbar C., Hale G., Waldmann H., Steinberg S., Slavin S. Allogeneic bone marrow transplantation for leukemia using CAMPATH 1 monoclonal antibody and post transplant immunization with donor lymphocytes. Exp Hematol. 21:1993;1061a. (abstr).
36. Kaplan E., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457.
37. Cox D. Regression models and lifetables. J Royal Stat Soc. 34(B):1972;187.
38. McCann S.R., Bacigalupo A., Gluckman E., Hinterberger W., Hows J., Ljungman P., Marin P., Nissen C., van't-Veer-Kurthof E., Raghavachar A. Graft rejection and second bone marrow transplants for acquired aplastic anemia. a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group Bone Marrow Transplant. 13:1994;233.
39. Sanders J.E., Storb R., Anasetti C., Deeg H.J., Donney K., Sullivan K.M., Witherspoon R.P., Hansen J. Marrow transplant experience for children with severe aplastic anemia. Am J Pediatr Hematol Oncol. 16:1994;43.
40. Uharek L., Gassman W., Glass B., Steinmann J., Loeffer H., Muller-Ruchholtz W. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood. 79:1992;1612.
41. Janossy G., Prentice H.G., Grob J.P. T lymphocyte regeneration after transplantation of T cell depleted allogeneic bone marrow. Clin Exp Immunol. 63:1986;577.
42. Martin P.J. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipients alloantigens. potential role of a veto mechanism Blood. 88:1998;962.
43. Storb R., Doney K.C., Thomas E.D., Appelbaum F., Buckner C.D., Clift R.A., Deeg H.J., Goodell B.W., Hackman R., Hansen J.A., Sanders J., Sullivan K., Weiden P.L., Witherspoon R.P. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood. 59:1982;236.
44. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D. Graft versus leukemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood. 86:1995;2041.
45. Mackinnon S., Papadopoulos E.B., Carabasi M.H., Reich L., Collins N.H., Boulad F., Castro-Malaspina H., Childs B.H., Gillio A.P., Kernan N.A. Adoptive immunotherapy evaluating escalating doses of donor leukocyte for relapse of chronic myeloid leukemia after bone marrow transplantation. separation of graft versus leukemia response from graft versus host disease Blood. 86:1995;1261.
46. Slavin S., Naparstek E., Nagler A., Ackerstein A., Kapelushnik J., Or R. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 23:1995;1553.
47. Helenglass G., Powles R.L., McElvain T.J., Lakhani A., Milan S., Gore N., Nandi A., Zuiable A., Perren T., Forgeson G., Treleavan J., Hamilton C., Millar J. Melphalan and TBI versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplantation for acute myeloblastic leukemia in first remission. Bone Marrow Transplant. 3:1988;21.
48. Schmitz N., Gassmann W., Rister M., Johannson W., Suttorp M., Brix F., Holthuis J., Heit W., Hertenstein B., Schaub J., Loeffler H. Fractionated total body irradiation and high dose VP16-213 followed by allogeneic bone marrow transplantation in advanced leukemias. Blood. 72:1988;1567.
49. Slavin S., Fuks Z., Kaplan H.S., Strober S. Transplantation of allogeneic bone marrow without graft vs. host disease using total lymphoid irradiation. J Exp Med. 147:1978;963.
50. Slavin S., Weiss L., Morecki S., Weigensberg M., Fuks Z. Immunosuppression and induction of transplantation tolerance by fractionated total lymphoid irradiation. Slavin S. Tolerance in bone marrow and organ transplantation. 1984;105 Elsevier Science, Amsterdam.
51. Naparstek E., Nagler A., Or R., Slavin S. Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies. Cecka J.M., Terasaki P.I. Clinical transplants. 1996;281 UCLA, Los Angeles.
52. Gerritsen W.R., Wagemaker G., Jonker M., Kenter M.J.H., Wielenga J.J., Hale G., Waldmann H., van Bekkum D.W. The repopulating capacity of bone marrow grafts following pretreatment with monoclonal antibodies against T lymphocytes in Rhesus monkeys. Transplantation. 45:1988;310.
53. Lapidot T., Lubin I., Tereni A., Faktorowich Y., Erlich P., Reisner Y. Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity. Proc Natl Acad Sci USA. 87:1990;4595.
54. Sykes M., Sheard M., Sachs D.H. Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence of donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD. J Immunol. 141:1988;2282.
55. Sykes M., Chester C.H., Sundt T.M., Romick M.L., Hoyles K.A., Sachs D.H. Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell population that increases allogeneic chimerism independently of graft vs. host disease in mixed marrow recipients. J Immunol. 143:1989;3503.